Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Complix has won €1.9m grant to advance the development of cell penetrating Alphabodies (CPABs) to address various intracellular diseases.
Subscribe to our email newsletter
The Flanders government has awarded the grant through the agency for innovation by science and technology, IWT.
Complix CEO Dr Mark Vaeck said the results generated so far indicate that the platform has the potential to transform the pharmaceutical industry’s ability to address the class of potential drug targets, namely intracellular protein-protein interactions (PPIs).
"Although intracellular PPIs are known to be involved in a variety of important disease processes, such as cancer, autoimmunity, CNS and metabolic diseases, most of them have been found intractable by small chemicals or antibodies," Vaeck added.
Alphabodies are potent small single chain alpha-helical proteins that can penetrate and act on intracellular protein targets.
Key properties of Alphabodies that can deal with a range of undruggable disease targets include high specificity, stability in human serum and effectiveness on large protein targets.